Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO bitopertin trial in erythropoietic protoporphyria and X-linked protoporphyria
NL-OMON60083Phase 3Completed
- Sponsor
- Disc Medicine
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) comparing Bitopertin with Placebo (2 arms). Primary endpoints: Average monthly total time in sunlight on days without pain from a phototoxic reaction, Percent change from baseline in whole-blood metal-free PPIX and 1 more. Started Oct 2025; status: completed.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NL-OMON60083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60083.